Merck is developing and evaluating the enzyme lysine-specific demethylase 1 (LSD1), Bomedemstat. LSD1 is an epigenetic regulator of gene expression critical for regulating myelopoiesis. Inhibition of LSD1 had profound effects on the natural history of myelofibrosis and essential thrombocythemia in mouse models of those diseases. To learn more, please www.merck.com